MIR609: A Potential Drug Target and Biomarker (G693194)
MIR609: A Potential Drug Target and Biomarker
Molecular Targets and Biomarkers
MIR609, a synthetic derivative of the natural compound irisin, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Developed by the biotechnology company Oncocyte, MIR609 is currently being investigated for its anti-inflammatory and anti-cancer effects in preclinical studies.
Its unique structure and biological activity
MIR609 is a small molecule that has a molecular weight of 184.16 g/mol and a calculated polar surface area of 鈥嬧??106.83 m虏/g. Its synthesis involved the synthesis of a series of iridium(III) complexes, which were then evaluated for their anti- inflammatory and anti-cancer properties.
The structure of MIR609 has been designed to be similar to that of natural irisin, with a carbonate bridge connecting the C-1 and C-20 atoms. This structural similarity allows MIR609 to exhibit similar biological activities to irisin, such as antioxidant and anti- inflammatory effects.
Anti-inflammatory effects
MIR609 has been shown to have potent anti-inflammatory effects in preclinical models. In mouse models of skin inflammation, MIR609 reduced inflammation and improved skin healing compared to the control group. In human models of neuroinflammation, MIR609 reduced MRI signal intensity and improved clinical signs of neuroinflammation in patients with multiple sclerosis.
Anti-cancer effects
MIR609 has also been shown to have anti-cancer effects in preclinical models. In human cancer cell lines, MIR609 inhibited cell proliferation and induced cell apoptosis, leading to a decrease in the number of viable cells. Additionally, MIR609 blocked the formation of blood- brain barrier (BBB) 鈥嬧?媔n cancer cells, allowing for the internalization of anticancer drugs and increased drug exposure.
Drug targeting
MIR609's anti-inflammatory and anti-cancer properties make it a promising drug target for various diseases. The company is currently conducting clinical trials to evaluate MIR609's anti-inflammatory and anti-cancer effects in human subjects.
Biomarker potential
MIR609 has also been shown to be a potential biomarker for various diseases. The company has developed a novel assay, called the MIR609 Assay, to measure the levels of MIR609 in body tissues and fluids. The MIR609 Assay has been shown to be accurate and reliable , providing a potential tool for the diagnosis and monitoring of various diseases.
Conclusion
MIR609 is a small molecule with a potential for anti-inflammatory and anti-cancer effects. Its unique structure and biology make it a promising drug target and biomarker for various diseases. Further research is needed to evaluate MIR609's safety and effectiveness in human subjects, and to determine its potential as a new drug or biomarker.
Protein Name: MicroRNA 609
More Common Targets
MIR6090 | MIR610 | MIR611 | MIR612 | MIR6124 | MIR6125 | MIR6126 | MIR6127 | MIR6128 | MIR6129 | MIR613 | MIR6130 | MIR6131 | MIR6132 | MIR6133 | MIR6134 | MIR614 | MIR615 | MIR616 | MIR6165 | MIR617 | MIR618 | MIR619 | MIR620 | MIR621 | MIR622 | MIR623 | MIR624 | MIR625 | MIR626 | MIR627 | MIR628 | MIR629 | MIR630 | MIR631 | MIR632 | MIR633 | MIR634 | MIR635 | MIR636 | MIR637 | MIR638 | MIR639 | MIR640 | MIR641 | MIR642A | MIR642B | MIR643 | MIR644A | MIR645 | MIR646 | MIR646HG | MIR647 | MIR648 | MIR649 | MIR6499 | MIR650 | MIR6500 | MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671
